vs
Amarin Corp plc（AMRN）与CAMDEN NATIONAL CORP（CAC）财务数据对比。点击上方公司名可切换其他公司
CAMDEN NATIONAL CORP的季度营收约是Amarin Corp plc的1.4倍（$64.3M vs $45.1M），CAMDEN NATIONAL CORP净利率更高（34.0% vs -23.3%，领先57.3%），过去两年CAMDEN NATIONAL CORP的营收复合增速更高（22.6% vs -18.3%）
Amarin是一家1993年成立的爱裔美籍生物制药企业，总部分别设于爱尔兰都柏林与美国新泽西州布里奇沃特。该企业专注研发及销售心血管疾病治疗药物，已推出处方级Omega-3脂肪酸药物Vascepa（AMR-101）。
卡姆登国民银行是一家总部位于美国缅因州卡姆登的商业银行，是上市银行控股公司卡姆登国民集团的核心子公司。该行创立于1875年，1984年完成企业重组后成为控股公司直接持有的全资子公司。2025年与诺斯韦金融合并后，合并后机构总资产约为70亿美元。
AMRN vs CAC — 直观对比
营收规模更大
CAC
是对方的1.4倍
$45.1M
净利率更高
CAC
高出57.3%
-23.3%
两年增速更快
CAC
近两年复合增速
-18.3%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $45.1M | $64.3M |
| 净利润 | $-10.5M | $21.9M |
| 毛利率 | — | — |
| 营业利润率 | 35.5% | — |
| 净利率 | -23.3% | 34.0% |
| 营收同比 | 7.0% | — |
| 净利润同比 | 33.0% | — |
| 每股收益（稀释后） | — | $1.29 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AMRNCAC
| Q1 26 | $45.1M | $64.3M | ||
| Q4 25 | $49.2M | $68.1M | ||
| Q3 25 | $49.7M | $65.4M | ||
| Q2 25 | $72.7M | $62.3M | ||
| Q1 25 | $42.0M | $60.1M | ||
| Q4 24 | $62.3M | $47.6M | ||
| Q3 24 | $42.3M | $45.0M | ||
| Q2 24 | $67.5M | $42.8M |
净利润AMRNCAC
| Q1 26 | $-10.5M | $21.9M | ||
| Q4 25 | $-1.2M | $22.6M | ||
| Q3 25 | $-7.7M | $21.2M | ||
| Q2 25 | $-14.1M | $14.1M | ||
| Q1 25 | $-15.7M | $7.3M | ||
| Q4 24 | $-48.6M | $14.7M | ||
| Q3 24 | $-25.1M | $13.1M | ||
| Q2 24 | $1.5M | $12.0M |
毛利率AMRNCAC
| Q1 26 | — | — | ||
| Q4 25 | 47.1% | — | ||
| Q3 25 | 44.7% | — | ||
| Q2 25 | 69.2% | — | ||
| Q1 25 | 59.8% | — | ||
| Q4 24 | -15.4% | — | ||
| Q3 24 | 38.5% | — | ||
| Q2 24 | 63.4% | — |
营业利润率AMRNCAC
| Q1 26 | 35.5% | — | ||
| Q4 25 | -12.9% | 41.5% | ||
| Q3 25 | -22.4% | 40.5% | ||
| Q2 25 | -22.0% | 28.5% | ||
| Q1 25 | -39.9% | 10.3% | ||
| Q4 24 | -84.3% | 38.7% | ||
| Q3 24 | -59.5% | 35.2% | ||
| Q2 24 | -0.8% | 34.7% |
净利率AMRNCAC
| Q1 26 | -23.3% | 34.0% | ||
| Q4 25 | -2.5% | 33.1% | ||
| Q3 25 | -15.6% | 32.4% | ||
| Q2 25 | -19.4% | 22.6% | ||
| Q1 25 | -37.4% | 12.2% | ||
| Q4 24 | -78.0% | 30.8% | ||
| Q3 24 | -59.4% | 29.1% | ||
| Q2 24 | 2.3% | 28.0% |
每股收益（稀释后）AMRNCAC
| Q1 26 | — | $1.29 | ||
| Q4 25 | $0.00 | $1.33 | ||
| Q3 25 | $-0.02 | $1.25 | ||
| Q2 25 | $-0.03 | $0.83 | ||
| Q1 25 | $-0.04 | $0.43 | ||
| Q4 24 | $-0.12 | $1.00 | ||
| Q3 24 | $-0.06 | $0.90 | ||
| Q2 24 | $0.00 | $0.81 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $307.8M | — |
| 总债务越低越好 | — | $514.4M |
| 股东权益账面价值 | — | $710.0M |
| 总资产 | $645.8M | $7.0B |
| 负债/权益比越低杠杆越低 | — | 0.72× |
8季度趋势，按日历期对齐
现金及短期投资AMRNCAC
| Q1 26 | $307.8M | — | ||
| Q4 25 | $302.6M | — | ||
| Q3 25 | $286.6M | — | ||
| Q2 25 | $298.7M | — | ||
| Q1 25 | $281.8M | — | ||
| Q4 24 | $294.2M | — | ||
| Q3 24 | $305.7M | — | ||
| Q2 24 | $306.7M | — |
总债务AMRNCAC
| Q1 26 | — | $514.4M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
股东权益AMRNCAC
| Q1 26 | — | $710.0M | ||
| Q4 25 | $459.3M | $696.6M | ||
| Q3 25 | $458.9M | $676.4M | ||
| Q2 25 | $464.9M | $652.1M | ||
| Q1 25 | $473.7M | $640.1M | ||
| Q4 24 | $486.2M | $531.2M | ||
| Q3 24 | $531.4M | $529.9M | ||
| Q2 24 | $551.9M | $508.3M |
总资产AMRNCAC
| Q1 26 | $645.8M | $7.0B | ||
| Q4 25 | $670.8M | $7.0B | ||
| Q3 25 | $659.8M | $7.0B | ||
| Q2 25 | $670.1M | $6.9B | ||
| Q1 25 | $655.7M | $7.0B | ||
| Q4 24 | $685.3M | $5.8B | ||
| Q3 24 | $750.6M | $5.7B | ||
| Q2 24 | $799.9M | $5.7B |
负债/权益比AMRNCAC
| Q1 26 | — | 0.72× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AMRN
| U.S | $35.6M | 79% |
| Europe | $4.9M | 11% |
| Rest-of-World (ROW) | $2.8M | 6% |
| Licensing & Royalties | $1.8M | 4% |
CAC
| Net Interest Income | $52.4M | 81% |
| Noninterest Income | $12.0M | 19% |
